0.9564
10-一月-25 16:45:00
15 分钟延时
股票
-0.0286
-2.90%
今日范围
0.9260 - 0.9809
ISIN
N/A
来源
NASDAQ
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)
04 3月 2021 07:00:01 条件 Nasdaq GlobeNewswire
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
25 2月 2021 08:00:01 条件 Nasdaq GlobeNewswire
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
26 1月 2021 08:00:02 条件 Nasdaq GlobeNewswire